

Patent foramen ovale and migraine

Migraine is a complex disorder in which many psychological, environmental, biochemical, neurophysiologic, and genetic factors may play a role to trigger attacks.^{1,2}

Although its course is usually benign and it tends to abate with age, migraine has long been suspected as a risk factor for stroke. A number of case-control studies and a recent meta-analysis have demonstrated that the relative risk of stroke is as follows in the following groups of migraineurs compared with nonmigraineurs:³⁻⁶

- 1.83 in people with migraine without aura
- 2.27 in people with migraine with aura
- 8.27 in female migraineurs who smoke and take oral contraceptives.

Furthermore, migraineurs are more likely to exhibit silent ischemic lesions on magnetic resonance imaging.⁷

■ STROKE RISK AND THE PFO-MIGRAINE ASSOCIATION

The mechanisms by which migraine conveys an increased risk of stroke had been an object of speculation⁶ until the discoveries that the prevalence of patent foramen ovale (PFO) is the same in patients with migraine with aura as in patients with cryptogenic stroke⁸⁻¹⁰ and that the frequency of migraine in PFO-associated cryptogenic stroke is twice what would otherwise be expected.^{11,12} These findings have prompted a twofold hypothesis:^{13,14}

(1) That the association with PFO accounts for the increased stroke risk in patients with migraine through the mechanism of paradoxical brain embolism

(2) That the presence of a right-to-left shunt could serve as a conduit for chemicals that would be normally inactivated by the pulmonary filter to reach the systemic circulation and exert a trigger effect on hyperexcitable neurons.

The latter point would imply that, to a certain extent, PFO may cause migraine attacks. However, PFO and migraine are common conditions and their co-occurrence in a single patient might be coincidental;

alternately, PFO and migraine both could derive from a common underlying disorder (eg, a dysfunction in the endothelium) without necessarily being linked in a causal relationship.¹⁴

Nevertheless, a number of recent findings tend to support an etiologic link.

We recently assessed the extent of right-to-left shunt with contrast-enhanced transcranial Doppler imaging in 420 consecutive patients.¹⁵ Patients with prior stroke had larger shunts than patients without prior stroke (mean bubble count of 91 vs 58, respectively, on transcranial Doppler). Migraineurs with and without aura both had significantly larger shunts than nonmigraineurs (bubble counts of 104, 74, and 46, respectively). As detailed in **Table 1**, patients with both migraine and prior stroke had larger shunts than migraineurs without prior stroke, than nonmigraineurs with prior stroke, and than patients without migraine or prior stroke.

Possible effect of shunt size

These findings suggest that shunt size may have a dose effect in terms of the risk of having migraine and stroke. The plausible hypothesis is that, via the atrial septal defect, a venous-to-arterial passage of activated platelets or chemical substances may trigger headache by overwhelming the filtering capacity of the lung.¹⁶

Larger shunt might also increase the likelihood of paradoxical embolization to the brain and hence explain the statistically significant increase in stroke risk that is associated with migraine. The presence of a right-to-left shunt may be the most potent trigger of attacks in migraine with aura as well as migraine without aura and may be the main determinant of aura.

Specificity to migraine with aura

However, any interpretation of a causal link between PFO and migraine needs to take into account the fact that although PFO is found in nearly half of patients who have migraine with aura, its frequency in migraine without aura is the same as in nonmigraineurs.^{9,10}

For migraine with aura, a common inheritable trait linking migraine with atrial septal abnormalities has

* Dr. Anzola reported that he has no financial relationships that pose a potential conflict of interest with this article.

been suggested by Wilmschurst et al, who studied 71 relatives of 20 probands with a significantly sized atrial shunt.¹⁷ When the proband had migraine with aura and an atrial shunt, 15 of 21 (71.4%) first-degree relatives with a significant right-to-left shunt also had migraine with aura compared with 3 of 14 (21.4%) first-degree relatives without a significant shunt ($P < .02$), which suggests that migraine trait may be inherited in association with atrial shunts, at least in some kinships, and that the occurrence of atrial shunts is consistent with autosomal dominant inheritance.

CAN PFO CLOSURE IMPROVE MIGRAINE?

Further along the migraine-PFO connection are the effects of PFO closure on migraine severity. When Wilmschurst et al observed serendipitously that PFO closure to prevent decompression sickness in a cohort of scuba divers resulted in a dramatic decrease of migraine severity,¹⁸ this finding raised considerable interest on the possible curative effect of atrial septal repair on migraine. A number of subsequent publications reported a consistent benefit on migraine following PFO closure in patients who had suffered a stroke.^{19–24} The cumulative results of such studies are presented in **Table 2**. Although the validity of these results is limited by major methodologic flaws (retrospective design, lack of a control group, subjective rating of migraine severity, short follow-up, presence of previous stroke in all patients), recent findings from a prospective case-control study²⁵ have substantially confirmed the favorable effect of PFO closure on migraine, although to a somewhat less dramatic extent (see **Table 2**).

MIST trial raises questions

However, in partial contrast with these results are the recently reported findings of the Migraine Intervention with STARFlex Technology (MIST) trial,²⁶ the first prospective, multicenter, randomized, double-blind, placebo-controlled trial designed to evaluate the efficacy of PFO closure with the STARFlex® septal repair implant (NMT Medical, Inc., Boston, MA) to prevent refractory migraine headaches. The MIST trial enrolled patients with migraine with aura and moderate to large PFO as assessed by contrast-enhanced transthoracic echocardiography (TTE); patients had to have at least 5 days of migraine in the month preceding enrollment and their migraines had to be refractory to at least two different prophylactic medications. The primary outcome measure was the proportion of patients without headache at 6 months. Of 432 screened patients, 163

TABLE 1
Age and shunt according to cerebrovascular history and migraine status*

	No migraine		Migraine	
	No prior stroke	Prior stroke	No prior stroke	Prior stroke
No. patients	100	85	139	96
Sex (M/F)	40/60	38/47	21/118	18/78
Age, yr (mean \pm SD) [†]	48 \pm 17	55 \pm 14	36 \pm 14	42 \pm 11
Mean bubble count (SE) [‡]	38 (5)	55 (8)	72 (8)	123 (24)

* In a series of 420 consecutive patients undergoing transcranial Doppler imaging.¹⁵ See text for details.

[†] Age significantly different in all comparisons (P between $<.0001$ and $.023$).

[‡] Mean bubble count in migraine patients with prior stroke was significantly higher than in any other group (P between $<.0001$ and $.038$).

Reprinted, with permission, from Anzola GP, et al. Different degrees of right-to-left shunting predict migraine and stroke. Data from 420 patients. *Neurology* 2006; 66:765–767.

were found suitable for randomization and 147 were actually randomized to the interventional ($n = 74$) or sham ($n = 73$) arms. At 6-month follow-up, three patients in each arm were migraine-free, which corresponds to a 4% response rate in each arm and a clearly nonsignificant difference between the groups. A secondary post hoc outcome measure, the proportion of patients with a 50% reduction in the number of headache days, showed a statistically significant difference favoring the interventional arm (42% vs 23%, $P = .038$).

The results of the MIST trial generate more questions than answers in that they are presently published solely on the Web and in slide format, and a substantial amount of information is lacking; for instance, the proportion of residual shunts is unknown, as is the proportion of patients who experienced a worsening of their migraines, which has been reported to occur in the initial postoperative period.^{16,27} Furthermore, the use of transthoracic echocardiography as the only tool to quantify the amount of shunt and to discriminate between true PFO and atrial septal defect is questionable. Finally, the inclusion criterion of high frequency of migraine attacks, far exceeding the expected frequency of pure migraine with aura, may have allowed the enrollment of patients with mixed forms of headache, including episodic tension-type headache, which has proved unresponsive to PFO closure.²⁰

TABLE 2**Summary of results of nonrandomized trials on the effects of patent foramen ovale closure on migraine***

Author	Year	Type of study	No. of pts	Mean follow-up (months)	Patients with resolution (%)	Patients with improvement (%)
Wilmshurst et al ¹⁸	2000	Retrospective	21	17	48	38
Morandi et al ¹⁹	2003	Prospective	17	12	29	59
Schwerzmann et al ²⁰	2004	Retrospective	47	24	Not reported	83
Post et al ²¹	2004	Retrospective	26	6	84	Not reported
Azarbal et al ²²	2005	Retrospective	37	3	60	40
Reisman et al ²³	2005	Retrospective	50	12	56	14
Giardini et al ²⁴	2006	Retrospective	35	20	83	8
Overall results of retrospective trials			233	13	60	40
Anzola et al ²⁵	2006	Prospective case-control	50	12	38	48

* The only case-control study (reference 25) is contrasted with earlier reports.

PINPOINTING WHO MIGHT BENEFIT FROM PFO CLOSURE

Taken at face value, however, the MIST trial results put the therapeutic efficacy of atrial septal repair in a more realistic perspective. The hypothesis that PFO closure improves migraine needs further refinement and has to be stated in different terms, such as with the qualification that a proportion of patients with PFO-associated migraine might, in principle, benefit from PFO closure. Preliminarily, we need to identify which clinical features are most likely to be related to the presence of a right-to-left shunt. In other words, we need to identify the shunt-associated migraine syndrome.

From preliminary results of an ongoing Italian study,²⁸ it seems that some features help to differentiate patients in whom the right-to-left shunt may exert a pathophysiologic effect: being a female with a positive family history of migraine with aura and a higher frequency of migraine attacks with aura vs without aura appears to represent the core specificity of shunt-associated migraine (Anzola et al, unpublished data).

Future randomized controlled trials comparing PFO closure with medical treatments will have to incorporate the knowledge of which features are pathophysiologically related to PFO in migraine sufferers in order to enroll only those patients in whom investigating PFO closure in a randomized trial is worthwhile.

Finally, it is worth recalling that, even if transcatheter closure of PFO is a safe, effective, and minimally invasive procedure, a number of complications have been reported. Among these, special emphasis

should be placed on major arrhythmias, including supraventricular paroxysmal tachycardia and atrial fibrillation, which have been documented in up to 8% of patients within 1 month of the procedure.^{29,30}

REFERENCES

1. Welch KMA. Contemporary concepts of migraine pathogenesis. *Neurology* 2003; 61(Suppl 4): S2–S8.
2. Silberstein SD. Migraine. *Lancet* 2004; 363:381–391.
3. Chang CL, Donaghy M, Poulter N. Migraine and stroke in young women: case-control study. The World Health Organisation Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. *BMJ* 1999; 318:13–18.
4. Carolei A, Marini C, de Matteis G. History of migraine and risk of cerebral ischaemia in young adults. *Lancet* 1996; 347:1503–1506.
5. Tzourio C, Tehindrazanarivelo A, Iglesias S, et al. Case-control study of migraine and risk of ischaemic stroke in young women. *BMJ* 1995; 310:830–833.
6. Etminan M, Takkouche B, Isorna FC, Samii A. Risk of ischaemic stroke in people with migraine: systematic review and meta-analysis of observational studies. *BMJ* 2005; 330:63–66.
7. Kruit MC, Van Buchem MA, Hofman PA, et al. Migraine as a risk factor for subclinical brain lesions. *JAMA* 2004; 291:427–434.
8. Del Sette M, Angeli S, Leandri M, et al. Migraine with aura and right-to-left shunt on transcranial Doppler: a case-control study. *Cerebrovasc Dis* 1998; 8:327–330.
9. Anzola GP, Magoni M, Guindani M, Rozzini L, Dalla Volta G. Potential source of cerebral embolism in migraine with aura: a transcranial Doppler study. *Neurology* 1999; 52:1622–1625.
10. Domitrz I, Mieszkowski J, Kwicinski H. Prevalence of patent foramen ovale in patients with migraine. *Neurol Neurochir Pol* 2004; 38:89–92.
11. Lamy C, Giannesini C, Zuber M, et al, for the Patent Foramen Ovale and Atrial Septal Aneurysm Study Group. Clinical and imaging findings in cryptogenic stroke patients with and without patent foramen ovale. The PFO-ASA Study. *Stroke* 2002; 33:706–711.
12. Sztajzel R, Genoud D, Roth S, Mermillod B, Le Floch-Rohr J. Patent foramen ovale, a possible cause of symptomatic migraine: a study of 74 patients with acute ischemic stroke. *Cerebrovasc Dis* 2002; 13:102–106.
13. Wilmshurst P, Nightingale S. The role of cardiac and pulmonary pathology in migraine: a hypothesis. *Headache* 2006; 46:429–434.

14. Schwedt TJ, Dodick DW. Patent foramen ovale and migraine—bringing closure to the subject. *Headache* 2006; 46:663–671.
15. Anzola GP, Morandi E, Casilli F, Onorato E. Different degrees of right-to-left shunting predict migraine and stroke. Data from 420 patients. *Neurology* 2006; 66:765–767.
16. Beda RD, Gill EA Jr. Patent foramen ovale: does it play a role in the pathophysiology of migraine headache? *Cardiol Clin* 2005; 23:91–96.
17. Wilmshurst PT, Pearson MJ, Nightingale S, Walsh KP, Morrison WL. Inheritance of persistent foramen ovale and atrial septal defects and the relation to familial migraine with aura. *Heart* 2004; 90:1315–1320.
18. Wilmshurst PT, Nightingale S, Walsh KP, Morrison WL. Effect on migraine of closure of cardiac right-to-left shunts to prevent recurrence of decompression illness or stroke or for haemodynamic reasons. *Lancet* 2000; 356:1648–1651.
19. Morandi E, Anzola GP, Angeli S, Melzi G, Onorato E. Transcatheter closure of patent foramen ovale: a new migraine treatment? *J Intervent Cardiol* 2003; 16:39–42.
20. Schwerzmann M, Wiher S, Nedeltchev K, et al. Percutaneous closure of patent foramen ovale reduces the frequency of migraine attacks. *Neurology* 2004; 62:1399–1401.
21. Post MC, Thijs V, Herroelen L, Budts WL. Closure of a patent foramen ovale is associated with a decrease in prevalence of migraine. *Neurology* 2004; 62:1439–1440.
22. Azarbal B, Tobis J, Suh W, Chan V, Dao C, Gaster R. Association of interatrial shunts and migraine headaches Impact of transcatheter closure *J Am Coll Cardiol* 2005; 45:489–492.
23. Reisman M, Christofferson RD, Jesurum J, et al. Migraine headache relief after transcatheter closure of patent foramen ovale. *J Am Coll Cardiol* 2005; 45:493–495.
24. Giardini A, Donti A, Formigari R, et al. Transcatheter patent foramen ovale closure mitigates aura migraine headaches abolishing spontaneous right-to-left shunting. *Am Heart J* 2006; 151:922.e1–922.e5.
25. Anzola G, Frisoni GB, Morandi E, Casilli F, Onorato E. Shunt-associated migraine responds favorably to atrial septal repair: a case-control study. *Stroke* 2006; 37:430–434.
26. Dowson A. Migraine Intervention with STARFlex Technology (MIST) Trial. Slides presented at: American College of Cardiology Scientific Session 2006. Available at: www.clinicaltrialresults.org.
27. Wilmshurst PT, Nightingale S, Walsh KP, Morrison WL. Clopidogrel reduces migraine with aura after transcatheter closure of persistent foramen ovale and atrial septal defects. *Heart* 2005; 91:1173–1175.
28. Del Sette M, Dinia L, Finocchi C, et al. SAM (Shunt Associated Migraine) study: studio multicentrico osservazionale su emicrania e shunt destro-sinistro al TCD [abstract]. Presented at: Italian Stroke Forum 2005. Available at: <http://www.strokeforum.org/Stroke2005/Abstracts.htm>.
29. Khairy P, O'Donnell C, Landzberg MJ. Transcatheter closure versus medical therapy of patent foramen ovale and presumed paradoxical thromboemboli. A systematic review. *Ann Intern Med* 2003; 139:753–760.
30. Anzola GP, Morandi E, Casilli F, Onorato E. Does transcatheter closure really “shut the door”? a prospective study with transcranial doppler. *Stroke* 2004; 35:2140–2144.

Address: Gian Paolo Anzola, MD, Service of Neurology, S. Orsola Hospital FBF, Via Vittorio Emanuele II, 27, 25100 Brescia, Italy; gpanzola@numerica.it.